Core Viewpoint - The article emphasizes the importance of confirming the sustainability of stock trends for successful short-term investing, highlighting that price movements should be supported by strong fundamentals and positive earnings estimates [1][2]. Group 1: Stock Performance - Catalyst Pharmaceutical (CPRX) has shown a solid price increase of 5.2% over the past 12 weeks, indicating investor confidence in its potential upside [4]. - The stock has also maintained a price increase of 3.8% over the last four weeks, suggesting that the upward trend is still intact [5]. - CPRX is currently trading at 86.8% of its 52-week high-low range, indicating a potential breakout opportunity [5]. Group 2: Fundamental Strength - CPRX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises [6]. - The stock has an Average Broker Recommendation of 1 (Strong Buy), reflecting high optimism from the brokerage community regarding its near-term price performance [7]. Group 3: Investment Strategy - The article suggests that investors can utilize the "Recent Price Strength" screen to identify stocks like CPRX that are on an uptrend supported by strong fundamentals [3]. - There are over 45 Zacks Premium Screens available for investors to find stocks that align with their personal investing styles [8].

Company Overview - Catalyst Pharmaceutical (CPRX) shares increased by 16.7% to close at $22.80, following a notable trading volume that exceeded typical levels [1] - The stock had previously experienced an 11.7% decline over the past four weeks [1] Recent Developments - The rise in stock price was linked to a settlement agreement with Teva Pharmaceuticals regarding patent litigation for Firdapse (amifampridine), resolving issues related to Teva's abbreviated new drug application for a generic version [2] Financial Expectations - Catalyst is projected to report quarterly earnings of $0.52 per share, reflecting a year-over-year decrease of 1.9%, while revenues are expected to reach $132.71 million, marking a 20% increase from the previous year [3] - The consensus EPS estimate for Catalyst has remained unchanged over the last 30 days, indicating stability in earnings expectations [4] Industry Context - Catalyst operates within the Zacks Medical - Drugs industry, where Ionis Pharmaceuticals (IONS) has seen a 2.5% decline in its stock price, with a return of -8.6% over the past month [4] - Ionis Pharmaceuticals has a consensus EPS estimate of -$1.13, which represents a significant year-over-year decline of 1783.3% [5]

Core Viewpoint - Catalyst Pharmaceuticals has entered into a Settlement Agreement with Teva Pharmaceuticals to resolve patent litigation regarding the generic version of FIRDAPSE, ensuring that Teva cannot market its generic version before February 25, 2035, if approved by the FDA [1][2]. Company Overview - Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for rare diseases, with a commitment to patient care and accessibility [4]. - The company has a strong presence in the U.S. and is actively seeking to expand its global footprint through strategic partnerships [4]. - Catalyst was recognized as one of North America's Fastest-Growing Companies on the 2024 Deloitte Technology Fast 500™ List [4]. Legal and Regulatory Aspects - The Settlement Agreement will terminate all ongoing patent litigation between Catalyst/SERB and Teva regarding FIRDAPSE patents in the U.S. District Court for the District of New Jersey [2]. - The confidential license agreement will be submitted to the U.S. Federal Trade Commission and the U.S. Department of Justice for review as required by law [3].

Core Viewpoint - The article discusses the Zacks Style Scores, which are designed to help investors identify stocks with the best chances of outperforming the market over the next 30 days, focusing on growth, momentum, and value characteristics. Group 1: Zacks Style Scores Overview - The Zacks Style Scores are categorized into four types: Growth Score, Momentum Score, Value Score, and VGM Score, each assessing different aspects of a stock's performance [2][10][19]. - Each stock is rated from A to F based on its value, growth, and momentum characteristics, with A being the highest score indicating a better chance of outperforming [9]. - The Style Scores are intended to complement the Zacks Rank, which is based on earnings estimate revisions, to aid in stock selection [5][20]. Group 2: Catalyst Pharmaceuticals (CPRX) Analysis - Catalyst Pharmaceuticals, Inc. (CPRX) is highlighted as a stock to watch, currently holding a Momentum Style Score of B and experiencing a 1.9% increase in share price over the past four weeks [6][16]. - CPRX has a Zacks Rank of 3 (Hold) and a VGM Score of A, indicating a solid position among stocks [15][16]. - For fiscal 2024, five analysts have revised their earnings estimates upwards, with the Zacks Consensus Estimate increasing by $0.10 to $2.02 per share, and CPRX has an average earnings surprise of 18% [24].

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.Zacks Premium also includes the Zacks Style Scores. What are the Zacks Style Scores? Developed alon ...

CORAL GABLES, Fla., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Richard J. Daly, President and CEO of Catalyst will present at the 43rd Annual J.P. Morgan Healthcare Conference taking place January 13-16, 2025 in San Francisco, CA. 43rd Annual J.P ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium includes access to the Zacks Style Scores as we ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium also includes the Zacks Style Scores. What are the Zacks Style Scores? The Zacks Style ...

CORAL GABLES, Fla., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), today announced it ranked number 452 on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 30th year. The 2024 Deloitte Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2020 to 2023, for which Cata ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium includes access to the Zacks Style Scores as well. What are the Zacks Style Scores? The Z ...